BACE1 and Alzheimer disease: Most drugs that reduce the Aβ levels in AD are reported to fail due to side effects, such as verubecestat (BACE-1 inhibitor) and avagacestat (gamma-secretase inhibitor), warranting the development of safer drugs [8,9].